JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 26, 2008; DOI: 10.1124/jpet.108.143123


0022-3565/09/3281-28-39$20.00
JPET 328:28-39, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.143123v1
328/1/28    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hougaard, C.
Right arrow Articles by Rønn, L. C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hougaard, C.
Right arrow Articles by Rønn, L. C. B.

NEUROPHARMACOLOGY

A Positive Modulator of KCa2 and KCa3 Channels, 4,5-Dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591), Inhibits Bladder Afferent Firing in Vitro and Bladder Overactivity in Vivo

C. Hougaard, M. O. Fraser1, C. Chien1, A. Bookout, M. Katofiasc1, B. S. Jensen, F. Rode, J. Bitsch-Nørhave, L. Teuber, K. B. Thor1, D. Strøbæk, E. C. Burgard1, and L. C. B. Rønn

NeuroSearch A/S, Pederstrupvej, Ballerup, Denmark (C.H., B.S.J., F.R., J.B.-N., L.T., D.S., L.C.B.R.); and Dynogen Pharmaceuticals Inc., Durham, North Carolina (M.O.F., C.C., A.B., M.K., K.B.T., E.C.B.)

Calcium-activated potassium channels are attractive targets for the development of therapeutics for overactive bladder. In the current study, we addressed the role of calcium-activated potassium channels of small (SK; KCa2) and intermediate (IK; KCa3) conductance in bladder function pharmacologically. We identified and characterized a novel positive modulator of SK/IK channels, 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591). In whole-cell patch-clamp experiments, NS4591 doubled IK-mediated currents at a concentration of 45 ± 6 nM(n = 16), whereas 530 ± 100 nM (n = 7) was required for doubling of SK3-mediated currents. In acutely dissociated bladder primary afferent neurons, the presence of SK channels was verified using apamin and 1-ethyl-2-benzimidazolinone. In these neurons, NS4591 (10 µM) inhibited the number of action potentials generated by suprathreshold depolarizing pulses. NS4591 also reduced carbachol-induced twitches in rat bladder detrusor rings in an apamin-sensitive manner. In vivo, NS4591 (30 mg/kg) inhibited bladder overactivity in rats and cats induced by capsaicin and acetic acid, respectively. In conclusion, the present study supports the involvement of calcium-activated potassium channels in bladder function and identifies NS4591 as a potent modulator of IK and SK channels that is effective in animal models of bladder overactivity.


Received July 4, 2008; accepted September 25, 2008.

Address correspondence to: Dr. Lars Christian B. Rønn, NeuroSearch A/S, Pederstrupvej 93, DK-2750, Ballerup, Denmark. E-mail: lcr{at}neurosearch.dk







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.